Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Everus Construction Group Q1 2026 Earnings Call - Record Backlog and Margin Expansion Fuel Raised Guidance
Everus Construction Group delivered a powerful start to 2026, reporting record Q1 revenues of $1.04 billion and a 44% surge in EBITDA. The company’s disciplined approach to project selection and contr...
- Q1 2026 revenues reached a record $1.04 billion, a 25% increase from the prior year period, driven by robust growth across both the E&M and T&D segments.
- EBITDA surged 44% to $88.9 million, with EBITDA margins expanding 110 basis points to 8.6%, reflecting strong project execution and favorable weather conditions.
- Backlog hit a record $3.68 billion, up 20% year-over-year, with the E&M segment backlog growing 22% and T&D backlog increasing 10%.
- +7 more takeaways
Abeona Therapeutics Q1 2026 Earnings Call - ZEVASKYN Launch Momentum Surges as PSMA CAR-T Pipeline Expansion Signals Strategic Pivot
Abeona Therapeutics delivered a pivotal first quarter for its flagship gene therapy ZEVASKYN, with revenue jumping to $8.7 million as commercial traction accelerates. The company treated five patients...
- ZEVASKYN revenue surged to $8.7 million in Q1 2026, up from $2.4 million in Q4 2025, driven by three commercial treatments and early market traction.
- Five patients have been treated with ZEVASKYN to date, with six additional patients expected to undergo biopsies this quarter, signaling accelerating commercial momentum.
- Abeona activated two new Qualified Treatment Centers (QTCs), bringing the total to six, including Children’s Hospital of Philadelphia and NewYork-Presbyterian/Columbia University.
- +7 more takeaways
Milestone Pharma Q1 2026 Earnings Call - CARDEMYST Launch Gains Traction as ReVeRA-301 AFib Trial Begins
Milestone Pharmaceuticals reported its first partial quarter of commercial sales for CARDEMYST (etripamil), generating $0.2 million in revenue against a $26.1 million net loss. The launch is showing e...
- CARDEMYST (etripamil) generated $0.2 million in product revenue in Q1 2026, marking the first partial quarter of commercial sales since launch.
- Approximately 600 total prescriptions were written through the end of April, with steady month-over-month growth from 100 scripts in February to 300 in April.
- Over 400 unique healthcare professionals prescribed CARDEMYST to approximately 560 unique patients, indicating broad early adoption across cardiology (50%) and electrophysiology (25%).
- +7 more takeaways
Altimmune Q1 2026 Earnings Call - Pemvidutide Phase III Trial Launch and $535M Balance Sheet Secure Runway to 2029
Altimmune has secured its financial footing with a $225 million oversubscribed public offering, bringing its cash balance to $535 million. This runway fully funds operations through the Phase III MASH...
- Completed an oversubscribed public offering in April 2026, raising $225 million in gross proceeds and boosting the cash balance to $535 million as of April 30, 2026.
- The current cash position fully funds Altimmune’s operations through the Phase III MASH 52-week data readout expected in 2029, eliminating near-term dilution risk.
- Initiation of the global Phase III PERFORMA trial in MASH is targeted for the second half of 2026, with final protocol alignment secured from both the FDA and EMA.
- +7 more takeaways
Flex LNG Q1 2026 Earnings Call - Geopolitical Shock Drives Record Spot Rates and Upgraded Guidance
Flex LNG delivered a quarter defined by operational discipline and a geopolitical windfall. Q1 revenues of $78 million (excluding EUAs) and adjusted net income of $16.9 million were bolstered by the s...
- Q1 2026 revenues reached $78 million excluding EUAs, with adjusted net income of $16.9 million ($0.31 EPS), driven by operational efficiency and favorable spot market conditions.
- Fleet average Time Charter Equivalent (TCE) stood at $65,700 per day, reflecting strong utilization despite seasonal softness and scheduled dry dockings.
- Contract coverage for 2026 is now 91%, with 54 years of minimum backlog and potential to reach 81 years if all charter options are exercised.
- +12 more takeaways
EOG Resources Q1 2026 Earnings Call - Capital Reallocation to Oil and Record Cash Returns
EOG Resources kicked off 2026 with a strong operational and financial performance, generating $1.8 billion in adjusted net income and $1.5 billion in free cash flow. The company successfully beat guid...
- EOG Resources delivered exceptional Q1 2026 results, generating $1.8 billion in adjusted net income and $1.5 billion in free cash flow.
- The company beat guidance on production volumes, total per-unit cash operating costs, and DD&A, demonstrating strong operational execution.
- EOG increased its full-year 2026 oil production guidance by 2,000 bbl/day and NGL guidance by 6,000 bbl/day by reallocating capital from gas to oil-weighted assets.
- +9 more takeaways
Global-E Q1 2026 Earnings Call - Strong Q1 Beats Guidance, Raised Full-Year Outlook Amid Middle East Headwinds
Global-E delivered a robust Q1 2026, beating guidance across the board with GMV up 40% and adjusted EBITDA margins expanding to nearly 20%. The company raised its full-year outlook for GMV, revenue, a...
- GMV surged 40% year-over-year to $1.74 billion in Q1 2026, driven by strong consumption and successful new merchant onboarding.
- Revenue grew 33% to $252 million, with service fee take rates holding steady at 6.9% and fulfillment take rates at 7.5%.
- Adjusted EBITDA jumped 59% to $50.2 million, reflecting a 19.9% margin and demonstrating significant operational leverage.
- +7 more takeaways
Wix Q1 2026 Earnings Call - Proprietary LLM and Base44 ARR Surge Drive AI Strategy
Wix reported strong Q1 2026 results, with total bookings up 15% year-over-year to $585 million and revenue up 14% to $541 million. The company highlighted the rapid growth of its Base44 acquisition, w...
- Total bookings for Q1 2026 reached $585 million, a 15% year-over-year increase, while revenue grew 14% to $541 million.
- Base44, acquired earlier this year, achieved $150 million in ARR by mid-May, accelerating from $100 million ARR in early March, signaling strong momentum in the AI app creation market.
- New cohort bookings surged 46% year-over-year, driven by improved conversion rates and higher monetization from the recently launched Wix Harmony platform.
- +7 more takeaways
FRP Holdings Q1 2026 Earnings Call - Industrial Leasing Revival Offsets Near-Term FFO Pressure
FRP Holdings reported a mixed Q1 2026, with mining royalties providing a bright spot of 15% year-over-year growth while industrial and multifamily segments faced headwinds. The company generated $8.9 ...
- FRP Holdings generated $8.9 million in NOI and $3.6 million in FFO ($0.19 per share) for Q1 2026, ending with $130 million in liquidity.
- Mining and royalties segment drove profit growth, with NOI up 15% year-over-year to $3.8 million, providing durable, high-margin cash flow.
- Commercial and industrial occupancy fell to 47.5% from 85% last year, primarily due to lease rollover timing and slower tenant decision cycles, not lack of demand.
- +7 more takeaways
Costamare Bulkers Holdings Limited Q1 2026 Earnings Call - Derisking Balance Sheet with Cargill Deal and Fleet Renewal
Costamare Bulkers Holdings Limited reported a solid Q1 2026 with adjusted net income of $12.4 million, driven by robust dry bulk demand across Capesize, Panamax, and Supramax segments. The company has...
- Q1 adjusted net income reached $12.4 million, or $0.51 per share, reflecting strong operational performance.
- Legacy trading portfolio transfer to Cargill is substantially complete, with only one vessel remaining to be novated by year-end.
- Net cash position stands at approximately $127 million as of Q1 end, providing flexibility for countercyclical growth.
- +7 more takeaways